Updated Analysis of an Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

被引：2
|
作者：
Coyle, Luke
Morley, Nicholas J.
Rambaldi, Alessandro
Mason, Kylie D.
Verhoef, Gregor
Furness, Caroline
Desai, Rajendra
Mergen, Noemi
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141117
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma
    Goy, A
    Younes, A
    McLaughlin, P
    Pro, B
    Romaguera, JE
    Hagemeister, F
    Fayad, L
    Dang, NH
    Samaniego, F
    Wang, M
    Broglio, K
    Samuels, B
    Gilles, F
    Sarris, AH
    Hart, S
    Trehu, E
    Schenkein, D
    Cabanillas, F
    Rodriguez, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) : 667 - 675
  • [32] Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: Retrospective study
    Aurer, I
    Durakovic, N
    Radman, I
    Nemet, D
    Zupancic-Salek, S
    Kovacevic-Metelko, J
    Bogdanic, V
    Sertic, D
    Mrsic, M
    Mikulic, M
    Labar, B
    CROATIAN MEDICAL JOURNAL, 2002, 43 (05) : 550 - 554
  • [33] Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma
    Ansell, Stephen M.
    Witzig, Thomas E.
    Inwards, David J.
    Porrata, Luis F.
    Ythier, Arnaud
    Ferrande, Lee
    Nestorov, Ivan
    Devries, Todd
    Dillon, Stacey R.
    Hausman, Diana
    Novak, Anne J.
    CLINICAL CANCER RESEARCH, 2008, 14 (04) : 1105 - 1110
  • [34] Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma
    Nagai, Hirokazu
    Ogura, Michinori
    Kusumoto, Shigeru
    Takahashi, Naoto
    Yamaguchi, Motoko
    Takayama, Nobuyuki
    Kinoshita, Tomohiro
    Motoji, Toshiko
    Ohyashiki, Kazuma
    Kosugi, Hiroshi
    Matsuda, Shin
    Ohnishi, Kazunori
    Omachi, Ken
    Hotta, Tomomitsu
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 86 (02) : 117 - 123
  • [35] Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
    Pan, Jonathan
    Ghimire, Sushil
    Alpdogan, S. Onder
    Chapman, Andrew
    Carabasi, Matthew
    DiMeglio, Martina
    Gong, Jerald
    Martinez-Outschoorn, Ubaldo
    Rose, Lewis
    Ramirez, Michael
    Wagner, John L.
    Weiss, Mark
    Flomenberg, Neal
    Pro, Barbara
    Porcu, Pierluigi
    Filicko-OHara, Joanne
    Gaballa, Sameh
    LEUKEMIA & LYMPHOMA, 2021, 62 (03) : 590 - 597
  • [36] Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
    Schade, Jake R.
    Kim, Charles
    Drill, Esther
    Qiu, Annie
    Batlevi, Connie Lee
    Caron, Philip
    Colbourn, Donald Steven
    Hamilton, Audrey
    Hamlin, Paul A.
    Horwitz, Steven M.
    Intlekofer, Andrew M.
    Joffe, Erel
    von Keudell, Gottfried R.
    Kumar, Anita
    Noy, Ariela
    Okwali, Michelle
    Owens, Colette
    Palomba, M. Lia
    Rodriguez-Rivera, Ildefonso
    Sauter, Craig S.
    Schoder, Heiko
    Straus, David J.
    Vardhana, Santosha
    Younes, Anas
    Zelenetz, Andrew D.
    Matasar, Matthew J.
    BLOOD, 2019, 134
  • [37] Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan
    Izutsu, Koji
    Ando, Kiyoshi
    Nishikori, Momoko
    Shibayama, Hirohiko
    Teshima, Takanori
    Kuroda, Junya
    Kato, Koji
    Imaizumi, Yoshitaka
    Nosaka, Kisato
    Sakai, Rika
    Hojo, Seiichiro
    Nakanishi, Tadashi
    Rai, Shinya
    CANCER SCIENCE, 2021, 112 (09) : 3627 - 3635
  • [38] Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
    Ogura, Michinori
    Uchida, Toshiki
    Taniwaki, Masafumi
    Ando, Kiyoshi
    Watanabe, Takashi
    Kasai, Masanobu
    Matsumoto, Yosuke
    Shimizu, Daisuke
    Ogawa, Yoshiaki
    Ohmachi, Ken
    Yokoyama, Hiroki
    Tobinai, Kensei
    CANCER SCIENCE, 2010, 101 (09) : 2054 - 2058
  • [39] A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
    Ogura, Michinori
    Ando, Kiyoshi
    Suzuki, Tatsuya
    Ishizawa, Kenichi
    Oh, Sung Yong
    Itoh, Kuniaki
    Yamamoto, Kazuhito
    Au, Wing Yan
    Tien, Hwei-Fang
    Matsuno, Yoshihiro
    Terauchi, Takashi
    Yamamoto, Keiko
    Mori, Masahiko
    Tanaka, Yoshinobu
    Shimamoto, Takashi
    Tobinai, Kensei
    Kim, Won Seog
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (06) : 768 - 776
  • [40] An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma
    Andorsky, David J.
    Kolibaba, Kathryn S.
    Assouline, Sarit
    Forero-Torres, Andres
    Jones, Vicky
    Klein, Leonard M.
    Patel-Donnelly, Dipti
    Smith, Mitchell
    Ye, Wei
    Shi, Wen
    Yasenchak, Christopher A.
    Sharman, Jeff P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (02) : 215 - 222
12345